1.Patients with known hypersensitivity to any of the excipients of the study medication or to any other similar class of drugs. <br/ >2.Patients who participated in any other clinical trial of an experimental treatment for COVID-19 within 90 days prior to randomization. <br/ >3.Patients infected post vaccination of either 1st or 2nd dose. <br/ >4.Patients with one of the following symptoms at the time of screening. <br/ >a. Respiratory rate â?¥ 24/min, breathlessness <br/ >b. SpO2: â?¤ 93% on room air <br/ >5.Patients with pulse rate < 50 beats per minute at rest at the time of screening and randomization <br/ >6.Patients are currently hospitalized or expected to need hospitalization for COVID-19 within 48 hours of randomization. <br/ >7.Patients have hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3X upper limit of normal at screening. <br/ >8.Patients with platelet count <100,000/μL or received a platelet transfusion within 5 days prior to randomization. <br/ >9.Patients with AIDS-defining illness in the past 6 months. <br/ >10.Patients with uncontrolled co-morbid conditions such as hypertension, diabetes, cardiovascular disease, chronic lung/ liver/ kidney disease, cerebro-vascular disease as per the investigatorâ??s discretion. <br/ >11.Patients currently administering or anticipated to require Favipiravir, Oseltamivir or any other anti-viral treatments during study participation. <br/ >12. Patients with Absolute Neutrophil Count (ANC) < 500 mm3. <br/ >13.Patients currently administering immunosuppressive treatments within 30 days of prior to randomization or systemic corticosteroids. <br/ >14.Female patients who are pregnant and/ or breast feeding. <br/ >15.Patients who have any medical condition(s) or has any medical condition(s) which would likely interfere with the conduct or interpretation of the study as per the investigatorâ??s discretion <br/ >

1.Patients with known hypersensitivity to any of the excipients of the study medication or to any other similar class of drugs. <br/ >2.Patients who participated in any other clinical trial of an experimental treatment for COVID-19 within 90 days prior to randomization. <br/ >3.Patients infected post vaccination of either 1st or 2nd dose. <br/ >4.Patients with one of the following symptoms at the time of screening. <br/ >a. Respiratory rate â?¥ 24/min, breathlessness <br/ >b. SpO2: â?¤ 93% on room air <br/ >5.Patients with pulse rate < 50 beats per minute at rest at the time of screening and randomization <br/ >6.Patients are currently hospitalized or expected to need hospitalization for COVID-19 within 48 hours of randomization. <br/ >7.Patients have hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3X upper limit of normal at screening. <br/ >8.Patients with platelet count <100,000/μL or received a platelet transfusion within 5 days prior to randomization. <br/ >9.Patients with AIDS-defining illness in the past 6 months. <br/ >10.Patients with uncontrolled co-morbid conditions such as hypertension, diabetes, cardiovascular disease, chronic lung/ liver/ kidney disease, cerebro-vascular disease as per the investigatorâ??s discretion. <br/ >11.Patients currently administering or anticipated to require Favipiravir, Oseltamivir or any other anti-viral treatments during study participation. <br/ >12. Patients with Absolute Neutrophil Count (ANC) < 500 mm3. <br/ >13.Patients currently administering immunosuppressive treatments within 30 days of prior to randomization or systemic corticosteroids. <br/ >14.Female patients who are pregnant and/ or breast feeding. <br/ >15.Patients who have any medical condition(s) or has any medical condition(s) which would likely interfere with the conduct or interpretation of the study as per the investigatorâ??s discretion <br/ >

N/A

N/A

1.Patients with known hypersensitivity to any of the excipients of the study medication or to any other similar class of drugs. <br/ >2.Patients who participated in any other clinical trial of an experimental treatment for COVID-19 within 90 days prior to randomization. <br/ >3.Patients infected post vaccination of either 1st or 2nd dose. <br/ >4.Patients with one of the following symptoms at the time of screening. <br/ >a. Respiratory rate â?¥ 24/min, breathlessness <br/ >b. SpO2: â?¤ 93% on room air <br/ >5.Patients with pulse rate < 50 beats per minute at rest at the time of screening and randomization <br/ >6.Patients are currently hospitalized or expected to need hospitalization for COVID-19 within 48 hours of randomization. <br/ >7.Patients have hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3X upper limit of normal at screening. <br/ >8.Patients with platelet count <100,000/μL or received a platelet transfusion within 5 days prior to randomization. <br/ >9.Patients with AIDS-defining illness in the past 6 months. <br/ >10.Patients with uncontrolled co-morbid conditions such as hypertension, diabetes, cardiovascular disease, chronic lung/ liver/ kidney disease, cerebro-vascular disease as per the investigatorâ??s discretion. <br/ >11.Patients currently administering or anticipated to require Favipiravir, Oseltamivir or any other anti-viral treatments during study participation. <br/ >12. Patients with Absolute Neutrophil Count (ANC) < 500 mm3. <br/ >13.Patients currently administering immunosuppressive treatments within 30 days of prior to randomization or systemic corticosteroids. <br/ >14.Female patients who are pregnant and/ or breast feeding. <br/ >15.Patients who have any medical condition(s) or has any medical condition(s) which would likely interfere with the conduct or interpretation of the study as per the investigatorâ??s discretion <br/ >

1.Patients with known hypersensitivity to any of the excipients of the study medication or to any other similar class of drugs. <br/ >2.Patients who participated in any other clinical trial of an experimental treatment for COVID-19 within 90 days prior to randomization. <br/ >3.Patients infected post vaccination of either 1st or 2nd dose. <br/ >4.Patients with one of the following symptoms at the time of screening. <br/ >a. Respiratory rate â?¥ 24/min, breathlessness <br/ >b. SpO2: â?¤ 93% on room air <br/ >5.Patients with pulse rate < 50 beats per minute at rest at the time of screening and randomization <br/ >6.Patients are currently hospitalized or expected to need hospitalization for COVID-19 within 48 hours of randomization. <br/ >7.Patients have hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, hepatocellular carcinoma, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3X upper limit of normal at screening. <br/ >8.Patients with platelet count <100,000/μL or received a platelet transfusion within 5 days prior to randomization. <br/ >9.Patients with AIDS-defining illness in the past 6 months. <br/ >10.Patients with uncontrolled co-morbid conditions such as hypertension, diabetes, cardiovascular disease, chronic lung/ liver/ kidney disease, cerebro-vascular disease as per the investigatorâ??s discretion. <br/ >11.Patients currently administering or anticipated to require Favipiravir, Oseltamivir or any other anti-viral treatments during study participation. <br/ >12. Patients with Absolute Neutrophil Count (ANC) < 500 mm3. <br/ >13.Patients currently administering immunosuppressive treatments within 30 days of prior to randomization or systemic corticosteroids. <br/ >14.Female patients who are pregnant and/ or breast feeding. <br/ >15.Patients who have any medical condition(s) or has any medical condition(s) which would likely interfere with the conduct or interpretation of the study as per the investigatorâ??s discretion <br/ >